AUTL Stock — Autolus Therapeutics plc: Cash, EV, Pipeline

Share price

$1.94

Market cap

$516.4M

Cash

$201.6M

Enterprise value

$314.8M

Balance sheet

Cash	$201.6M
Debt	$0.0M
Net cash	$201.6M
Enterprise value	$314.8M
Basic shares	266.2M shares
Fully diluted shares	325.7M shares
Fully diluted market cap	$631.9M
Cash per share	$0.76

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AUTL daily closes…

Loading price history…

Pipeline assets

Obecabtagene autoleucel

Approved · Active Modality: CAR T cell therapy

Aliases AUCATZYL, obe-cel

Target CD19

Partnerships BioNTech License and Option Agreement: $40M upfront obe-cel revenue interest; company pays low single-digit % of net sales (up to mid-single digit for up to $100M milestones); Blackstone Collaboration: $50M upfront + 2x$35M development payments + $30M on FDA approval (all received); UCLB exclusive license (milestones including £6.0M EC approval milestone paid Q3 2025); Cardinal Health 105 commercial distribution partner (U.S.); AGC lentiviral vector manufacturing agreement (EUR 25M minimum purchase commitment)

Indications

Relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) (Approved)
Pediatric r/r B-ALL (CATULUS) (Phase 2)
Systemic lupus erythematosus (CARLYSLE) (Phase 1)
Lupus nephritis (LUMINA) (Phase 2)
Progressive multiple sclerosis (BOBCAT) (Phase 1)

Catalysts

— end of 2027
— Q4 2026
— 2028

Status note Fast off-rate CD19 CAR T. FDA BLA approved Nov 8, 2024 for adult (18+) r/r B-ALL; first U.S. sale Jan 2025; European Commission marketing approval Jul 18, 2025 (adult 26+ r/r B-ALL). Filing cites a ~$8M restructuring/realignment program in 2025-2026.

AUTO8

Phase 1 · Active Modality: CAR T cell therapy

Target CD19 (dual-targeting)

Indications

Light-chain amyloidosis (ALARIC) (Phase 1)

Catalysts

— end of 2026

Status note Dual-targeting CAR (second antigen not stated in the excerpts); Phase 1 ALARIC trial ongoing.

AUTO1/22

Stage not disclosed · Active Modality: CAR T cell therapy

Target CD19 (dual-targeting)

Status note Described in the 10-K fallback as a clinical-stage hematological cancer candidate using fast off-rate CD19 and dual-targeting CAR technology; no trial detail in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	4,447,910	no change	0.15%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

AUTL — Autolus Therapeutics plc

Balance sheet

Price history

Pipeline assets

Institutional holders